MCL-247: Durable Response of a Patient with a Mantle Cell Lymphoma Central Nervous System (CNS) Relapse to Treatment with a Bruton Tyrosine Kinase Inhibitor (BTKi) Monotherapy

2020 ◽  
Vol 20 ◽  
pp. S259-S260
Author(s):  
Adan Rios ◽  
Gregg Rekoff ◽  
Brian Dinh ◽  
Lei Chen ◽  
Amer Wahed ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Mantle Cell Lymphoma ◽  
Kinase Inhibitor ◽  
Cell Lymphoma ◽  
Durable Response ◽  
Mantle Cell ◽  
Bruton Tyrosine Kinase

scholarly journals Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

Blood ◽  
2013 ◽  
Vol 122 (14) ◽  
pp. 2412-2424 ◽  
Author(s):  
Betty Y. Chang ◽  
Michelle Francesco ◽  
Martin F. M. De Rooij ◽  
Padmaja Magadala ◽  
Susanne M. Steggerda ◽  
...  
Keyword(s):  
Tyrosine Kinase Inhibitor ◽  
Mantle Cell Lymphoma ◽  
Peripheral Blood ◽  
Kinase Inhibitor ◽  
Cell Lymphoma ◽  
Key Points ◽  
Mantle Cell ◽  
Bruton Tyrosine Kinase ◽  
Btk Inhibitor ◽  
And Migration

Key Points MCL cells are mobilized into the peripheral blood of patients treated with the BTK inhibitor ibrutinib. Ibrutinib dose-dependently inhibits BCR- and chemokine-mediated adhesion and migration of MCL cells.

Sign in / Sign up

Export Citation Format

Share Document